Ahmadzada Boyukkhanim, Felgendreff Philipp, Minshew Anna M, Amiot Bruce P, Nyberg Scott L
Research Trainee in the Division of Surgery Research (Ahmadzada; limited tenure), Artificial Liver and Liver Transplantation Laboratory (Minshew, Amiot, and Nyberg), and Division of Surgery Research (Nyberg), Mayo Clinic, Rochester, Minnesota, USA; Research Fellow in the Division of Surgery Research (Felgendreff), Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA. Dr Felgendreff is also affiliated with the Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
Curr Opin Biomed Eng. 2024 Sep;31. doi: 10.1016/j.cobme.2024.100537. Epub 2024 May 16.
The need for organ transplants exceeds donor organ availability. In the quest to solve this shortage, the most remarkable area of advancement is organ production through the use of chimeric embryos, commonly known as blastocyst complementation. This technique involves the combination of different species to generate chimeras, where the extent of donor cell contribution to the desired tissue or organ can be regulated. However, ethical concerns arise with the use of brain tissue in such chimeras. Furthermore, the ratio of contributed cells to host animal cells in the chimeric system is low in the production of chimeras associated with cell apoptosis. This review discusses the latest innovations in blastocyst complementation and highlights the progress made in creating organs for transplant.
器官移植的需求超过了供体器官的可获得性。在寻求解决这一短缺问题的过程中,最显著的进展领域是通过使用嵌合胚胎来生产器官,通常称为囊胚互补。这项技术涉及不同物种的组合以产生嵌合体,其中供体细胞对所需组织或器官的贡献程度可以得到调控。然而,在这种嵌合体中使用脑组织会引发伦理问题。此外,在与细胞凋亡相关的嵌合体生产中,嵌合系统中供体细胞与宿主动物细胞的比例较低。本文综述了囊胚互补的最新创新,并强调了在创建可用于移植的器官方面所取得的进展。